Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Hepatic Drug Excretion: Influencing Factors

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical characteristics and effects of inhaled corticosteroid in patients with post-COVID-19 chronic cough during the Omicron variant outbreak.

BMC pulmonary medicine·2024

Same author

Virus classification for viral genomic fragments using PhaGCN2.

Briefings in bioinformatics·2022

Same author

A discussion of RNA virus taxonomy based on the 2020 International Committee on Taxonomy of Viruses report.

Frontiers in microbiology·2022

Same author

A cycloartenol synthase from the steroidal saponin biosynthesis pathway of <i>Paris polyphylla</i>.

Journal of Asian natural products research·2020

Same author

Effects of chain length of saturated fatty acids on Aβ generation in SH-SY5Y cells.

Neuroscience letters·2019

Same author

[Changes of ocular higher order aberration in keratoconus eyes wearing rigid gas-permeable contact lens].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology·2011

Search research articles

Related Experiment Video

Updated: May 16, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Correlation between hepatitis B virus genotypes and clinical outcomes.

¹Qingdao YH Virus Institute, Shandong, China. yinghui_777＠163.com

Japanese Journal of Infectious Diseases

|November 28, 2012

Summary

Hepatitis B virus (HBV) genotypes significantly impact disease severity and treatment response. Genotypes C and D are linked to worse outcomes and HCC risk, while A and B respond better to interferon therapy.

More Related Videos

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Related Experiment Videos

Last Updated: May 16, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Area of Science:

Hepatology
Virology
Genetics

Background:

Hepatitis B virus (HBV) is classified into 10 genotypes (A-J) based on genome divergence.
HBV genotypes exhibit distinct geographical distributions, with B and C prevalent in Asia and A and D in Western regions.
Genotypes A, B, C, and D are the most extensively studied.

Purpose of the Study:

To review the clinical and epidemiological differences among HBV genotypes.
To explore the association between HBV genotypes and disease severity, including cirrhosis and hepatocellular carcinoma (HCC).
To examine the impact of HBV genotypes on therapeutic responses and treatment outcomes.

Main Methods:

Literature review of studies investigating HBV genotypes, their geographical distribution, and clinical implications.
Analysis of data correlating HBV genotypes with disease progression, HCC risk, and treatment efficacy.
Synthesis of findings on genotype-specific responses to interferon-alpha and other therapies.

Main Results:

Genotypes C and D are associated with more severe chronic hepatitis B, higher risks of cirrhosis and HCC, particularly in Asian men with specific HBV DNA levels and mutations.
Genotypes A and B are more frequently linked to acute hepatitis B in Europe and Asia.
Interferon-alpha treatment shows better efficacy in patients with genotypes A and B compared to C, D, and mixed genotypes.

Conclusions:

HBV genotypes display significant clinical and epidemiological variations influencing disease progression and treatment outcomes.
Further research is needed on HBV sub-genotypes, mixed infections, and novel therapies for poorly responding patients.
Understanding genotype-specific characteristics is crucial for developing targeted and effective HBV treatment strategies.